ST-400

N/A

Report date: 2024/10/24 20:00:07

Base Information

Drug NameST-400
Drug Alias NameST-400
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionBCL11A gene inhibitors
TargetsB-cell lymphoma/leukemia 11A
Therapy Area/Indicationsbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc
Inactive CompaniesN/A
Active Indicationsbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A